JP2012509071A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509071A5
JP2012509071A5 JP2011536741A JP2011536741A JP2012509071A5 JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5 JP 2011536741 A JP2011536741 A JP 2011536741A JP 2011536741 A JP2011536741 A JP 2011536741A JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid construct
invariant chain
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2009/050310 external-priority patent/WO2010057501A1/en
Publication of JP2012509071A publication Critical patent/JP2012509071A/ja
Publication of JP2012509071A5 publication Critical patent/JP2012509071A5/ja
Pending legal-status Critical Current

Links

JP2011536741A 2008-11-21 2009-11-20 免疫応答のプライミング Pending JP2012509071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801638 2008-11-21
DKPA200801638 2008-11-21
PCT/DK2009/050310 WO2010057501A1 (en) 2008-11-21 2009-11-20 Priming of an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014226711A Division JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング

Publications (2)

Publication Number Publication Date
JP2012509071A JP2012509071A (ja) 2012-04-19
JP2012509071A5 true JP2012509071A5 (https=) 2013-01-24

Family

ID=40823418

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011536741A Pending JP2012509071A (ja) 2008-11-21 2009-11-20 免疫応答のプライミング
JP2014226711A Pending JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング
JP2017011749A Pending JP2017131220A (ja) 2008-11-21 2017-01-26 免疫応答のプライミング
JP2019091809A Active JP6825036B2 (ja) 2008-11-21 2019-05-15 免疫応答のプライミング

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014226711A Pending JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング
JP2017011749A Pending JP2017131220A (ja) 2008-11-21 2017-01-26 免疫応答のプライミング
JP2019091809A Active JP6825036B2 (ja) 2008-11-21 2019-05-15 免疫応答のプライミング

Country Status (20)

Country Link
US (4) US20110293704A1 (https=)
EP (3) EP3552622A3 (https=)
JP (4) JP2012509071A (https=)
CN (3) CN104404068A (https=)
AU (1) AU2009317691A1 (https=)
BR (1) BRPI0921927B8 (https=)
CA (1) CA2743229A1 (https=)
CY (1) CY1122117T1 (https=)
DK (1) DK2865387T3 (https=)
ES (1) ES2743677T3 (https=)
HK (1) HK1209645A1 (https=)
HR (1) HRP20191594T1 (https=)
HU (1) HUE045093T2 (https=)
IL (4) IL212914A0 (https=)
LT (1) LT2865387T (https=)
PL (1) PL2865387T3 (https=)
PT (1) PT2865387T (https=)
RU (2) RU2017138373A (https=)
SI (1) SI2865387T1 (https=)
WO (1) WO2010057501A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
EP2575877B1 (en) * 2010-06-04 2016-10-19 INSERM - Institut National de la Santé et de la Recherche Médicale Novel immunoadjuvant compounds and uses thereof
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
CN104067125B (zh) 2011-12-07 2017-12-26 比利时意志有限责任公司 用于检测核小体加合物的方法
AU2013295647B2 (en) * 2012-07-26 2018-02-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
PL2968440T3 (pl) 2013-03-15 2019-12-31 Zymeworks Inc. Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
SG11201510747RA (en) * 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
AU2014373640B2 (en) * 2013-12-27 2018-08-30 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
AU2016339924B2 (en) * 2015-10-12 2020-01-02 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
MX2019002178A (es) * 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201704417D0 (en) * 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
JP7298926B2 (ja) * 2017-07-12 2023-06-27 ノイスコム アーゲー 癌の治療のためのネオアンチゲンワクチン組成物
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3078692A1 (en) * 2017-11-03 2019-05-09 Nouscom Ag Vaccine t cell enhancer
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN108285885A (zh) * 2017-12-28 2018-07-17 中国农业大学 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
KR20210081325A (ko) * 2018-10-19 2021-07-01 노우스콤 아게 경골어류 불변 사슬 암 백신
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
RU2725493C2 (ru) * 2018-12-28 2020-07-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора
TW202102256A (zh) 2019-03-05 2021-01-16 比利時商葛蘭素史密斯克藍生物品公司 B型肝炎免疫法及組合物
CN111729093B (zh) * 2020-06-29 2022-05-24 南京超维景生物科技有限公司 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587673A (en) 1897-08-03 higgins
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JP2682061B2 (ja) 1988-10-07 1997-11-26 藤沢薬品工業株式会社 ペプチドの分子内ジスルフィド結合の形成法
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
WO1997010335A1 (de) * 1995-09-14 1997-03-20 Universität Tübingen Rekombinantes polypeptid basierend auf der primärsequenz der invarianten kette mit mindestens einer primärsequenz von einem spezifischen t-zellepitop oder eines proteinderivats und dieses rekombinante polypeptid kodierende nukleinsäuren
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
EP1957528B1 (en) * 2005-11-30 2012-11-07 University of Copenhagen A nucleotide vaccine
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
US9085638B2 (en) * 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2344191A4 (en) * 2008-09-02 2013-02-13 Antigen Express Inc HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2012509071A5 (https=)
RU2011125306A (ru) Праймирование иммунного ответа
Yang et al. Cell-penetrating peptides: efficient vectors for vaccine delivery
JP6321261B2 (ja) ワクチン組成物及びその使用方法
Abdullah et al. Supramolecular self-assembled peptide-based vaccines: current state and future perspectives
Li et al. Rational design of T-cell-and B-cell-based therapeutic cancer vaccines
Zhang et al. Recent developments in intracellular protein delivery
Andrianov et al. Molecular-level interactions of polyphosphazene immunoadjuvants and their potential role in antigen presentation and cell stimulation
CA3036742A1 (en) Modified vsv-g and vaccines thereof
AU2016379413A1 (en) Covalent polymer-antigen conjugated particles
Wang et al. Cell penetrating peptide-based redox-sensitive vaccine delivery system for subcutaneous vaccination
US20040033585A1 (en) Flexible vaccine assembly and vaccine delivery platform
Bolhassani et al. DNA immunization as an efficient strategy for vaccination
Jiang Cell-penetrating peptide-mediated nanovaccine delivery
WO2022043449A1 (en) Vaccines based on an antigen protein fused to a nanostructuring scaffold
Yin et al. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses
CN104136039A (zh) 靶向交叉呈递的树突状细胞的疫苗体
Wang et al. Advances of nanotechnology toward vaccine development against animal infectious diseases
US20240207385A1 (en) Compositions comprising self-assembling vaccines and methods of using the same
JPWO2013147232A1 (ja) 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル
Bae et al. Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery
JP5901084B2 (ja) ペプチドアジュバント
CN118576725A (zh) 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用
WO2005091753A2 (en) Flexible vaccine assembly and vaccine delivery platform
US20050282263A1 (en) Flexible vaccine assembly and vaccine delivery platform